All In Biotech

Drug Trial Radar · NCT05126992

EU Secondary Data Post-Authorisation Safety Study of AZD1222

A Post-authorisation/Post-marketing Observational Study to Evaluate the Association Between Exposure to AZD1222 and Safety Concerns Using Existing Secondary Health Data Sources

Last checked: Nov 20, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5,321,930

Actual

Start

Feb 18, 2022

Primary completion

Jan 24, 2024

Study completion Jan 24, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
RTI Health Solutions
First posted
Nov 19, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study based on electronic heath records will evaluate the incidence and relative risk of safety concerns and adverse events of special interest (AESIs) following immunisation by AZD1222 in the real-world setting. A cohort and a self-controlled case series desings will be used.

Conditions

  • COVID-19, Vaccine Adverse Events of Special Interest

Interventions

  • AZD1222Biological

    Covid-19 AstraZeneca Vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events of special interestTime frame: up to 365 days

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Utrecht, Netherlands

  • Research Site

    Barcelona, Spain

  • Research Site

    Valencia, Spain

  • Research Site

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.